Monday
Innovation in action: moving forward with basal insulins in people with T2D
- Novo Nordisk A/S
- Monday, 9 September 2024
- 09:00 - 11:00 CEST
- Madrid Hall
Understanding and Preventing Hypoglycemia in Diabetes
- The Leona M. and Harry B. Helmsley Charitable Trust
- Monday, 9 September 2024
- 09:00 - 18:00 CEST
- Warsaw Hall
CGM as an Essential Companion Across Diabetes Management
- Abbott Diabetes Care
- Monday, 9 September 2024
- 10:30 - 12:00 CEST
- Sydney Hall
People, Populations and Practice: Exploring the Journey across Diabetes care
- SANOFI
- Monday, 9 September 2024
- 10:30 - 16:00 CEST
- Berlin Hall
Turning the tide: How can diabetologists make waves in weight management?
- AstraZeneca
- Monday, 9 September 2024
- 12:00 - 13:00 CEST
- Sofia Hall
Emerging therapies in heart and kidney disease: Effects and clinical implications of finerenone
- Bayer AG
- Monday, 9 September 2024
- 12:00 - 13:30 CEST
- Lima Hall
The three Gs in the context of gut hormone multiagonism
- Eli Lilly and Company
- Monday, 9 September 2024
- 13:00 - 14:30 CEST
- Cairo Hall
Thinking together: learnings from 3-real life cases to improve diabetes management and transform your clinical practice with CGM
- Dexcom
- Monday, 9 September 2024
- 13:00 - 14:30 CEST
- Mumbai Hall
The Kidney in Focus in Diabetes Care – Novel Strategies for Changing CKD Trajectory
- Medscape Global Education
- Monday, 9 September 2024
- 13:00 - 14:40
- Madrid Hall
Increasing the Tempo: Early initiation of SGLT2is for cardiorenal protection
- AstraZeneca
- Monday, 9 September 2024
- 13:30 - 15:00 CEST
- Sofia Hall
Expanding Horizons in Insulin Therapy: Applications of MiniMed™ 780G system and MDI solutions
- Medtronic International Trading Sàrl
- Monday, 9 September 2024
- 13:30 - 15:00 CEST
- Sydney Hall
Prepare, Prevent & Act: Unlocking the power of prediction for advanced in-time glycaemic control
- Roche Diabetes Care GmbH
- Monday, 9 September 2024
- 13:30 - 15:00 CEST
- Vienna Hall
The glucagon philharmonic: Orchestrating metabolic harmony in obesity, liver disease and health
- Boehringer Ingelheim International GmbH
- Monday, 9 September 2024
- 15:00 - 16:30 CEST
- Lima Hall
The Heart in Focus in Obesity Care – Lowering the CV Burden with Novel Weight Loss Therapies
- Medscape Global Education
- Monday, 9 September 2024
- 15:00 - 16:40
- Madrid Hall
Exploring therapeutic mechanisms to improve organ function in CVRM diseases
- AstraZeneca
- Monday, 9 September 2024
- 15:30 - 17:00 CEST
- Sofia Hall
iCan real-time CGM system: An option for all patient groups
- Sinocare Meditech Inc.
- Monday, 9 September 2024
- 16:00 - 17:00 CEST
- Mumbai Hall
Redefining T2D and Obesity Management: The First and Only Approved GIP and GLP-1 Receptor Agonist
- Eli Lilly and Company
- Monday, 9 September 2024
- 16:30 - 18:00 CEST
- Sydney Hall
Why Act? Expert Insights on the Value of Protection Against Vaccine-Preventable Disease in Patients with Diabetes
- GSK
- Monday, 9 September 2024
- 16:30 - 18:00 CEST
- Cairo Hall
Triple protection of SGLT2i: ACT2DAY for patients’ future
- Menarini Group
- Monday, 9 September 2024
- 17:00 - 18:00 CEST
- Vienna Hall
Tuesday
AI-assisted screening for diabetic retinopathy – real-life outcomes
- iCare
- Tuesday, 10 September 2024
- 08:45 - 08:55 CEST
- virtual only
Beta-cell dysfunction in T2D – is it irrevocable?
- Eli Lilly and Company
- Tuesday, 10 September 2024
- 12:00 - 12:30 CEST
- Spotlight Stage
Partner together to turn small steps into big wins
- Abbott
- Tuesday, 10 September 2024
- 14:45 - 15:15 CEST
- Spotlight Stage
Strengthening diagnosis and treatment of CKD in Type 1 Diabetes: current and future perspectives
- Sciarc GmbH
- Tuesday, 10 September 2024
- 16:45 - 17:15 CEST
- Spotlight Stage
The right time for Metformin
- Merck KGaA
- Tuesday, 10 September 2024
- 18:30 - 19:30 CEST
- Mumbai Hall
Improving adherence, glycemic control and outcomes for people living with diabetes
- Servier medical affairs
- Tuesday, 10 September 2024
- 18:30 - 19:30 CEST
- Warsaw Hall
At the crossroads of specialties: Exploring the trends in the holistic, person-centred approach in cardiovascular-kidney-metabolic disease
- Novo Nordisk A/S
- Tuesday, 10 September 2024
- 18:30 - 20:00 CEST
- Lima Hall
Wednesday
Conversations between specialties: the importance of SGLT2 inhibitor initiation for the interdisciplinary management of cardio, renal and metabolic conditions
- Boehringer Ingelheim and Eli Lilly and Company
- Wednesday, 11 September 2024
- 07:45 - 08:45 CEST
- Lima Hall
The Omnipod® 5 Era: Celebrating Success Through Transformational Person-Centered AID Care
- Insulet
- Wednesday, 11 September 2024
- 07:45 - 08:45 CEST
- Mumbai Hall
Powering up progress: How CGM insights are revolutionizing Type 2 diabetes care
- Abbott
- Wednesday, 11 September 2024
- 07:45 - 08:45 CEST
- Warsaw Hall
A New Technological Horizon: Optimizing Treatment with Tandem Diabetes Care
- Tandem Diabetes Care, Inc.
- Wednesday, 11 September 2024
- 08:15 - 08:45 CEST
- Beijing Hall
T2D care in the digital era: evidence with once-weekly insulins, CGM and other digital health tools
- Novo Nordisk A/S
- Wednesday, 11 September 2024
- 12:15 - 12:45 CEST
- Spotlight Stage
Tackling clinical inertia in Type 2 diabetes with Dexcom CGM
- Dexcom
- Wednesday, 11 September 2024
- 15:00 - 15:30 CEST
- Spotlight Stage
The need to look beyond BMI
- Eli Lilly and Company
- Wednesday, 11 September 2024
- 17:00 - 17:30 CEST
- Spotlight Stage
Heart failure, chronic kidney disease and diabetes: Improving outcomes with non-steroidal MRAs
- Sciarc GmbH
- Wednesday, 11 September 2024
- 18:45 - 19:45 CEST
- Beijing Hall
Obesity management in the spotlight: how can we achieve patient-centricity?
- Novo Nordisk A/S
- Wednesday, 11 September 2024
- 18:45 - 20:15 CEST
- Lima Hall
Embracing innovation in a new era of diabetes care: A CME Symposium
- IMNE // supported by an educational grant from Novo Nordisk A/S
- Wednesday, 11 September 2024
- 18:45 - 20:15 CEST
- Mumbai Hall
From Burden to Breakthrough: Reimagining Type 1 Diabetes Treatment With Cell-Based Approaches
- Vertex Pharmaceuticals, Inc.
- Wednesday, 11 September 2024
- 18:45 - 20:15 CEST
- Warsaw Hall
Thursday
Addressing the needs of all people living with type 1 diabetes
- Medtronic International Trading Sàrl
- Thursday, 12 September 2024
- 12:15 - 12:45 CEST
- Spotlight Stage
AI-based glucose predictions – bringing diabetes self-management to the next level
- Roche Diabetes Care GmbH
- Thursday, 12 September 2024
- 15:00 - 15:30 CEST
- Spotlight Stage
Breaking the barriers: Addressing the metabolic impact of MASH with multidisciplinary care
- Novo Nordisk A/S and Echosens
- Thursday, 12 September 2024
- 18:45 - 19:15 CEST
- Warsaw Hall
Entering a New Era in Metabolic Dysfunction-Associated Steatohepatitis: Examining the Clinical Implications of Emerging Disease-Specific Therapies
- AKH Inc. and Catalyst Medical Education, LLC. // supported by an educational grant from Madrigal Pharmaceuticals
- Thursday, 12 September 2024
- 18:45 - 19:45 CEST
- Lima Hall
Cholesterol Lowering in High Cardiovascular Risk Patients with Comorbidities: Closing Gaps and Future Opportunities
- DAIICHI SANKYO EUROPE GmbH
- Thursday, 12 September 2024
- 18:45 - 19:45 CEST
- Mumbai Hall
Management of CKD in T2D – where are we today?
- Novo Nordisk A/S
- Thursday, 12 September 2024
- 19:45 - 20:15 CEST
- Warsaw Hall
Friday
Multidisciplinary dialogue on non-invasive liver assessment in patients with obesity: from guidelines to clinical research
- Translational Medicine Academy (TMA)
- Friday, 13 September 2024
- 10:00 - 10:30 CEST
- Spotlight Stage
Enabling women with type 1 diabetes to achieve their goals with Automated Insulin Delivery
- Ypsomed AG
- Friday, 13 September 2024
- 11:30 - 12:00 CEST
- Spotlight Stage